Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorWright State University
About this trial
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.
Eligibility criteria
Qualifiers
Age 18 and older
Mild to severe plaque psoriasis (2% or greater Body Surface Area; Psoriasis Area and Severity Score of 2 or greater; Investigator Grade Assessment of mild-severe)
Disqualifiers
Currently taking medication that alters the normal ion balance of low-dose in blood.
No calcium supplements 1 month prior to baseline (not including multivitamins).
Unstable or uncontrolled illness, including but not limited to cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or psychiatric disease at screening.
Abnormal laboratory values at screening, that in the opinion of the investigator, would potentially affect patient safety or data integrity.
Trial design
Treatments tested in this trial
- Triamcinolone
- Vitamin D3
- Placebo
Treatment groups
24 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov